Career counseling with undocumented Latino youth

Storlie, Cassandra A.

doi:10.17077/etd.23xbc3ll

Cited by 3 publications

(4 citation statements)

References 79 publications

(220 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As career concerns are noted to be a part of the family constellation (Storlie & Byrd, 2016), choosing a major and a future occupation are two primary career decisions made among college freshmen and sophomores (Orndorff & Herr, 1996). Studies indicate that students with undeclared majors are more likely to drop out of college (Leppel, 2002; St.…”

Section: Literature Reviewmentioning

confidence: 99%

“…Postmodern and constructivist approaches have flourished within the field of career development over the last two decades (Chope, 2005), providing important insights into the impact of family on career exploration and choice (Storlie & Byrd, 2016). Constructivist and postmodern career approaches (Busacca & Rehfuss, 2016) bring clients’ narrative of past experiences into the present to support meaning making (Brott, 2005; Buxbaum & Hill, 2013).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Family Career Genograms: Beginning Life Design With Exploratory Students

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Literature Reviewmentioning

confidence: 99%

mentioning

confidence: 99%

Family Career Genograms: Beginning Life Design With Exploratory Students

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Low-dose glucocorticoids might also offer therapeutic benefits, albeit relatively modest, as demonstrated by results ofseveral retrospective analyses and a randomized trial showing prostate-specific antigen response rates of 22%-61% [56][57][58] and by results from the placebo-prednisone arms of COU-AA-301 and COU-AA-302 [4,5]. Particularly in COU-AA-302, lowdose prednisone behaved as an active comparator, producing objective responses defined by Response Evaluation Criteria in Solid Tumors in 16% of patients and a $50% decline in prostate-specific antigen levels in 24% of patients [5].…”

Section: Therapeutic or Adjunctive Use Of Glucocorticoids In Mcrpcmentioning

confidence: 99%

Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer

Auchus

Nguyen

et al. 2014

The Oncologist

View full text Add to dashboard Cite

Abiraterone acetate, a prodrug of the CYP17A1 inhibitor abiraterone that blocks androgen biosynthesis, is approved for treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with prednisone or prednisolone 5 mg twice daily.This review evaluatesthe basis for the effects of prednisone on mineralocorticoid-related adverse events that arise because of CYP17A1 inhibition with abiraterone. Coadministration with the recommended dose of glucocorticoid compensates for abiraterone-induced reductions in serum cortisol and blocks the compensatory increase in adrenocorticotropic hormone seen with abiraterone. Consequently, 5 mg prednisone twice daily serves as a glucocorticoid replacement therapy when coadministered with abiraterone acetate, analogous to use of glucocorticoid replacement therapy for certain endocrine disorders. We searched PubMed to identify safety concerns regarding glucocorticoid use, placing a focus on longitudinal studies in autoimmune and inflammatory diseases and cancer. In general, glucocorticoid-related adverse events, including bone loss, immunosuppression, hyperglycemia, mood and cognitive alterations, and myopathy, appear dose related and tend to occur at doses and/or treatment durations greater than the low dose of glucocorticoid approved in combination with abiraterone acetate for the treatment of mCRPC. Although glucocorticoids are often used to manage tumor-related symptoms or to prevent treatment-related toxicity, available evidence suggests that prednisone and dexamethasone might also offer modest therapeutic benefit in mCRPC. Given recent improvements in survival achieved for mCRPC with novel agents in combination with prednisone, the risks of these recommended glucocorticoid doses must be balanced with the benefits shown for these regimens. The Oncologist 2014;19:1231-1240 Implications for Practice: Abiraterone acetate, a prodrug of the CYP17A1 inhibitor abiraterone, suppresses testosterone and cortisol production in patients with metastatic castration-resistant prostate cancer (mCRPC), but cortisol precursors with mineralocorticoid activity rise during abiraterone acetate monotherapy. Low-dose prednisone (5 mg twice daily) coadministration serves as glucocorticoid replacement therapy, lowers adrenocorticotropic hormone, and reduces the incidence and severity of mineralocorticoid-related adverse events. In contrast, pharmacologic glucocorticoid doses used to treat other malignancies and autoimmune disorders are typically $20 mg/day prednisone equivalence, and these higher doses are associated with an adverse safety profile. The safety profile of low-dose glucocorticoid use in mCRPC deserves further study.

show abstract

“…When counselor educators were called to teach in uncertain times during the COVID‐19 pandemic, they were also challenged to recognize and integrate knowledge learned from the long‐term social unrest that has permeated our society (Storlie et al, 2021). Critical issues remain in counseling and counselor education related to dimensions of identity including but not limited to African Americans (Williams et al., 2021), Asian American and Pacific Islanders (Litam & Chan, 2021), gender (Macombs–Hunter & Bhat, 2020) and gender identity (Chavez‐Korell & Johnson, 2010), culture and ethnicity (Authors, 2021), and ability (Rivas & Hill, 2018).…”

Section: Introductionmentioning

confidence: 99%